EWTX
VENTE TOTALE: 23 872 titres (~1 042 009,74 $ US)
- Insiders
- Russell Alan J, KOCH KEVIN
- Total bought
- —
- Total sold
- $1,042,010
- Last activity
- 2026-08-12
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-16
EWTX's high liquidity score (85) is structurally misleading, reflecting post-asset-sale idle cash rather than any operational strength, while the fundamental trend score (15) confirms severe distress with zero revenue…
The first sentence of the analysis written for EWTX on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 19.853 | 19.928 | 19.498 | 21.525 | 26.972 | |
| Quick Ratio | 19.853 | 19.928 | 19.498 | 21.525 | 26.972 | |
| Solvency Ratio | -5.455 | -4.765 | -4.642 | -3.292 | -3.921 | |
| Cash Ratio | 2.234 | 1.746 | 5.134 | 1.326 | 1.480 | |
| Price To Earnings Ratio | -15.227 | -18.414 | -6.968 | -7.095 | -17.767 | |
| Price To Earnings Growth Ratio | -1.227 | 2.409 | -0.283 | -0.153 | -0.122 | |
| Forward Price To Earnings Growth Ratio | -1.227 | 2.409 | -0.283 | -0.153 | -0.122 | |
| Price To Earnings Diluted Ratio | -15.227 | -18.414 | -6.968 | -7.095 | -17.767 | |
| Price To Earnings Diluted Growth Ratio | -1.227 | 2.409 | -0.283 | -0.153 | -0.122 | |
| Price To Book Ratio | 4.892 | 5.373 | 2.187 | 1.382 | 2.757 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -17.764 | -22.362 | -7.136 | -8.235 | -22.132 | |
| Price To Operating Cash Flow Ratio | -17.764 | -22.632 | -7.582 | -9.103 | -22.573 | |
| Debt To Assets Ratio | 0.007 | 0.010 | 0.016 | 0.012 | 0.000 | |
| Debt To Equity Ratio | 0.008 | 0.010 | 0.017 | 0.013 | 0.000 | |
| Debt To Capital Ratio | 0.008 | 0.010 | 0.017 | 0.013 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.006 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.058 | 1.060 | 1.067 | 1.059 | 1.040 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.255 | -4.569 | -5.483 | -3.174 | -3.185 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.012 | 1.062 | 1.105 | 1.020 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -15.700 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -17.834 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -36.044 | -23.016 | -16.983 | -11.941 | 0.000 | |
| Capital Expenditure Coverage Ratio | -561.781 | -83.101 | -16.005 | -9.491 | -50.160 | |
| Dividend Paid And Capex Coverage Ratio | -561.781 | -83.101 | -16.005 | -9.491 | -50.160 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -15.088 | -18.480 | -6.263 | -7.316 | -17.414 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 19.853 | ▼-0.075 | ▼-1.702 |
| Quick Ratio | 19.853 | ▼-0.075 | ▼-1.702 |
| Solvency Ratio | -5.455 | ▼-0.690 | ▼-1.040 |
| Cash Ratio | 2.234 | ▲0.488 | ▼-0.150 |
| Price To Earnings Ratio | -15.227 | ▲3.187 | ▼-2.133 |
| Price To Earnings Growth Ratio | -1.227 | ▼-3.636 | ▼-1.352 |
| Forward Price To Earnings Growth Ratio | -1.227 | ▼-3.636 | ▼-1.352 |
| Price To Earnings Diluted Ratio | -15.227 | ▲3.187 | ▼-2.133 |
| Price To Earnings Diluted Growth Ratio | -1.227 | ▼-3.636 | ▼-1.352 |
| Price To Book Ratio | 4.892 | ▼-0.481 | ▲1.574 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -17.764 | ▲4.598 | ▼-2.238 |
| Price To Operating Cash Flow Ratio | -17.764 | ▲4.868 | ▼-1.833 |
| Debt To Assets Ratio | 0.007 | ▼-0.003 | ▼-0.002 |
| Debt To Equity Ratio | 0.008 | ▼-0.003 | ▼-0.002 |
| Debt To Capital Ratio | 0.008 | ▼-0.003 | ▼-0.002 |
| Long Term Debt To Capital Ratio | 0.006 | ▲0.006 | ▲0.004 |
| Financial Leverage Ratio | 1.058 | ▼-0.002 | ▲0.002 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -5.255 | ▼-0.685 | ▼-0.921 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.012 | ▼-0.040 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲3.140 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲3.567 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -36.044 | ▼-13.028 | ▼-18.447 |
| Capital Expenditure Coverage Ratio | -561.781 | ▼-478.681 | ▼-417.674 |
| Dividend Paid And Capex Coverage Ratio | -561.781 | ▼-478.681 | ▼-417.674 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -15.088 | ▲3.392 | ▼-2.176 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.55B | $2.47B | $697.1M | $479.1M | $756.4M | |
| Enterprise value | $2.50B | $2.43B | $616.5M | $461.5M | $740.8M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -17.37x | -22.29x | -6.70x | -8.77x | -22.11x | |
| EV / Free cash flow | -17.37x | -22.03x | -6.31x | -7.93x | -21.68x | |
| EV / EBITDA | -15.09x | -18.48x | -6.26x | -7.32x | -17.41x | |
| Net debt / EBITDA | 0.34x | 0.28x | 0.82x | 0.28x | 0.37x | |
| Current ratio | 19.85x | 19.93x | 19.50x | 21.52x | 26.97x | |
| Income quality | 0.86x | 0.81x | 0.92x | 0.78x | 0.78x | |
| Graham net-net | $5 | $5 | $5 | $6 | $5 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 106.3% | 100.0% | |
| Working capital | $516.0M | $451.6M | $310.2M | $340.4M | $273.3M | |
| Invested capital | $525.2M | $462.7M | $322.9M | $350.3M | $274.2M | |
| Return on assets | -30.4% | -27.5% | -29.5% | -18.4% | -15.0% | |
| Operating ROA | -36.8% | -38.4% | -32.3% | -22.0% | -20.8% | |
| Return on tangible assets | -30.4% | -27.5% | -29.5% | -18.4% | -15.0% | |
| Return on equity | -32.1% | -29.1% | -31.4% | -19.5% | -15.6% | |
| Return on invested capital | -36.4% | -34.2% | -35.3% | -20.4% | -15.7% | |
| Return on capital employed | -36.4% | -34.3% | -35.4% | -20.4% | -15.7% | |
| Earnings yield | -6.6% | -5.4% | -14.4% | -14.1% | -5.7% | |
| Free cash flow yield | -5.6% | -4.5% | -14.0% | -12.1% | -4.5% | |
| Capex / Op. cash flow | -0.2% | -1.2% | -6.2% | -10.5% | -2.0% | |
| Capex / Depreciation | 11.3% | 57.3% | 331.7% | 1030.9% | 245.6% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 967d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -967d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+3.5%EV / Sales n/aEV / EBITDA ▲+18.4%EV / Op. cash flow ▲+4.926Earnings yield ▼-0.011
Profitability
Return on equity ▼-0.030Return on assets ▼-0.029Return on invested capital ▼-0.021Return on capital employed ▼-0.021Operating ROA ▲+0.016Income quality ▲+0.042Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.075Net debt / EBITDA ▲+0.065Working capital ▲+64392000.000Invested capital ▲+62538000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+237.8%EV / Sales n/aEV / EBITDA ▲+13.4%EV / Op. cash flow ▲+4.742Earnings yield ▼-0.009
Profitability
Return on equity ▼-0.165Return on assets ▼-0.154Return on invested capital ▼-0.206Return on capital employed ▼-0.207Operating ROA ▼-0.161Income quality ▲+0.074Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-7.119Net debt / EBITDA ▼-0.021Working capital ▲+242763000.000Invested capital ▲+251069000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-06 Edgewise Therapeutics Reports Second Quarter 2026 Financial Results – Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65 billion in July 2026, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline – BOULDER, Colo., Aug. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights.
- 2026-07-13 Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline — Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential approval — BOULDER, Colo., July 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, acquired sevasemten and Edgewise''s muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion.
- 2026-07-01 Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on June 30, 2026, Edgewise granted inducement stock options to purchase a total of 16,500 shares of Edgewise''s common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise''s 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
- 2026-06-17 Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
- 2026-06-16 Edgewise Therapeutics Reports Improvements In Heart Drug Trial Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial.
- 2026-06-16 Edgewise shares slip after heart-disease drug trial data disappoints investors Edgewise Therapeutics shares fell nearly 10% on Tuesday after the efficacy of its experimental heart-disease drug in a mid-stage study fell short of investor expectations.
- 2026-06-16 Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) – No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Time – BOULDER, Colo.
- 2026-06-04 Edgewise: ''Buy'' On Muscular Dystrophy Program Sale And EDG-7500 Advancement Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3.
- 2026-06-03 Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules BOULDER, Colo., June 3, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29, 2026, Edgewise granted inducement stock options to purchase a total of 74,000 shares of Edgewise''s common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise''s 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
- 2026-06-02 Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.